Rajeev Malhotra.

A publicly available e-mail address was used for a third attempt at contact if no response was obtained after two mailings. Case enrollment and identification are summarized in Physique 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. The consenting survivors and next of kin of nonsurvivors completed a questionnaire addressing demographic characteristics, history of running and other exercise, personal and family medical history, and information about the cardiac arrest. Permission was obtained to gain access to pertinent medical records, including information regarding visits to primary treatment and specialist offices and tests that took recognized place prior to the cardiac arrest, emergency-medical-service documentation of treatment at the time of the cardiac arrest, and medical center, autopsy, and outpatient records following the cardiac arrest.Dall, and C. Gruendker, for the AGO Study Group, details the use of AEZS-108, a targeted cytotoxic drug where doxorubicin is linked to )-luteinizing hormone-releasing hormone , in females with histologically confirmed taxane-pretreated platinum-resistant/refractory LHRH-R positive advanced or recurrent ovarian cancer. Individuals received a recommended dose of 267 mg/m2 by intravenous infusion over 2 hours, with retreatment every 3 weeks, for to 6 courses up. Response price was thought as principal endpoint. Secondary endpoints had been basic safety, time-to-progression and general survival . Results 42 patients with platinum-resistant ovarian cancers entered the study.